IRVINE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Masimo , the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that a new peer-reviewed clinical study published in this month’s Inhalation Toxicology demonstrates that Masimo Rainbow SET(R) Pulse CO-Oximetry (SpCO) provides reliable measurements of carbon monoxide (CO) in the blood that facilitate fast, accurate diagnosis of CO poisoning in pre-hospital emergency and rescue environments.(1)
Dr. Piatkowski and colleagues at the University Hospital Aachen (Germany) used the Masimo Rad-57 Pulse CO-Oximeter to measure SpCO in 20 patients suspected of CO poisoning who were admitted to the burn center and in five healthy volunteers (used as a control group). Comparing SpCO measurements to COHb measurements obtained hourly via invasive blood samples processed using three different laboratory analyzers, researchers found that the mean error of the three different blood gas analyzers was just 1% lower than noninvasive Pulse CO-Oximetry. The SpCO measurements from Pulse CO-Oximetry resulted in a mean error of approximately 3.15% over a COHb range of 1% to 38%, while the invasive COHb measurements from three different blood analyzers resulted in a mean error of 2.4%. Researchers concluded that Pulse CO-Oximetry “represents a reliable measurement technique that is easy to handle and could facilitate the early diagnosis of CO intoxication in pre-hospital rescue conditions.”
(1) A. Piatkowski, D. Ulrich, G. Grieb, N. Pallua. “A New Tool for the Early Diagnosis of Carbon Monoxide Intoxication.” Inhalation Toxicology, November 2009; 21(3):1144-1147.
About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care - helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.” Additional information about Masimo and its products may be found at www.masimo.com.
CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348
Web site: http://www.masimo.com/
